RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase

Kyung-Hun Lee(Seoul National University), Yung‐Jue Bang(Seoul National University), Do‐Youn Oh(Seoul National University Hospital), Seock‐Ah Im(Seoul National University), Sang‐Hyun Song(Seoul National University), Ju‐Hee Lee(Dongguk University), Hyung-Seok Hur(Seoul National University), Hwang‐Phill Kim(Ulsan College), Young‐Kwang Yoon(Seoul National University), Tae‐You Kim(Seoul National University Hospital), Sae‐Won Han(Seoul National University Hospital)
Cancer Letters
August 20, 2010
10.1016/j.canlet.2010.07.020
Cited by 69

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k